Israel Englander Prothena Corp Public LTD CO Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Millennium Management LLC holds 31,292 shares of PRTA stock, worth $676,220. This represents 0.0% of its overall portfolio holdings.

Number of Shares

31,292

Previous 322,241 90.29%

Holding current value

$676,220

Previous $7.98 Million 91.92%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$19.54 - $26.15 $5.69 Million - $7.61 Million	-290,949 Reduced 90.29%	31,292 $645,000
Q1 2024 May 15, 2024	BUY	$24.75 - $40.66 $7.04 Million - $11.6 Million	284,585 Added 755.75%	322,241 $7.98 Million
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $147,204 - $238,369	4,556 Added 13.76%	37,656 $1.37 Million
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $7.8 Million - $12.7 Million	-161,539 Reduced 82.99%	33,100 $2.26 Million
Q1 2023 May 15, 2023	SELL	$46.97 - $58.27 $891,067 - $1.11 Million	-18,971 Reduced 8.88%	194,639 $9.43 Million
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $4.38 Million - $5.47 Million	84,173 Added 65.03%	213,610 $12.9 Million
Q3 2022 Nov 14, 2022	SELL	$25.16 - $60.63 $1.89 Million - $4.56 Million	-75,233 Reduced 36.76%	129,437 $7.85 Million
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $1.55 Million - $2.72 Million	-68,005 Reduced 24.94%	204,670 $5.56 Million
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $1.6 Million - $2.6 Million	52,784 Added 24.0%	272,675 $9.97 Million
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $2.87 Million - $5 Million	68,222 Added 44.98%	219,891 $10.9 Million
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $3.07 Million - $5.03 Million	63,725 Added 72.46%	151,669 $10.8 Million
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $1.41 Million - $3.75 Million	64,988 Added 283.1%	87,944 $4.52 Million
Q1 2021 May 17, 2021	SELL	$11.0 - $28.24 $5.8 Million - $14.9 Million	-527,314 Reduced 95.83%	22,956 $577,000
Q4 2020 Feb 16, 2021	SELL	$10.12 - $13.94 $1.71 Million - $2.35 Million	-168,869 Reduced 23.48%	550,270 $6.61 Million
Q3 2020 Nov 16, 2020	BUY	$9.93 - $13.47 $737,918 - $1 Million	74,312 Added 11.52%	719,139 $7.18 Million
Q2 2020 Aug 14, 2020	BUY	$9.56 - $12.51 $76,642 - $100,292	8,017 Added 1.26%	644,827 $6.75 Million
Q1 2020 May 14, 2020	BUY	$7.54 - $15.77 $833,479 - $1.74 Million	110,541 Added 21.0%	636,810 $6.81 Million
Q4 2019 Feb 14, 2020	SELL	$7.48 - $17.01 $5.25 Million - $11.9 Million	-702,207 Reduced 57.16%	526,269 $8.33 Million
Q3 2019 Nov 14, 2019	BUY	$6.89 - $10.45 $4.77 Million - $7.23 Million	692,291 Added 129.11%	1,228,476 $9.63 Million
Q2 2019 Aug 15, 2019	BUY	$8.85 - $12.49 $2.46 Million - $3.47 Million	278,212 Added 107.85%	536,185 $5.67 Million
Q2 2019 Aug 14, 2019	BUY	$8.85 - $12.49 $2 Million - $2.82 Million	225,529 Added 695.13%	257,973 $7.23 Million
Q1 2019 May 14, 2019	SELL	$10.32 - $14.49 $397,505 - $558,125	-38,518 Reduced 54.28%	32,444 $394,000
Q4 2018 Feb 14, 2019	SELL	$8.73 - $13.74 $5.82 Million - $9.17 Million	-667,063 Reduced 90.38%	70,962 $731,000
Q3 2018 Nov 14, 2018	SELL	$12.7 - $15.79 $1.32 Million - $1.64 Million	-104,139 Reduced 12.37%	738,025 $9.65 Million
Q2 2018 Aug 14, 2018	SELL	$10.99 - $44.21 $320,303 - $1.29 Million	-29,145 Reduced 3.34%	842,164 $12.3 Million
Q1 2018 May 15, 2018	BUY	$27.95 - $45.04 $24.1 Million - $38.8 Million	862,283 Added 9553.32%	871,309 $32 Million
Q4 2017 Feb 14, 2018	BUY	$35.44 - $63.76 $319,881 - $575,497	9,026	9,026 $338,000

Others Institutions Holding PRTA

# of Institutions

182

Shares Held

42.7M

Call Options Held

77.7K

Put Options Held

92.7K

View Full List

About PROTHENA CORP PUBLIC LTD CO

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $1.01B
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

More about PRTA

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account